Published in Neurobiol Aging on September 11, 2006
Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging (2009) 2.14
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav (2008) 1.80
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol (2009) 1.44
Role of the ubiquitin proteasome system in Alzheimer's disease. BMC Biochem (2007) 1.25
Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease. J Biol Chem (2011) 1.23
Assessment and treatment of pain in people with dementia. Nat Rev Neurol (2012) 1.22
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm (Vienna) (2009) 1.22
Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front Aging Neurosci (2010) 1.20
Loss of modifier of cell adhesion reveals a pathway leading to axonal degeneration. J Neurosci (2009) 1.06
Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer's disease. Brain Struct Funct (2010) 1.04
Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease. Biochim Biophys Acta (2010) 1.01
Age-dependent and tissue-related glutathione redox status in a mouse model of Alzheimer's disease. J Alzheimers Dis (2012) 1.00
Familial amyloid precursor protein mutants cause caspase-6-dependent but amyloid β-peptide-independent neuronal degeneration in primary human neuron cultures. Cell Death Dis (2010) 0.96
Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo) (2011) 0.96
Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system. Exp Neurol (2012) 0.95
Quantitative in vivo measurement of early axonal transport deficits in a triple transgenic mouse model of Alzheimer's disease using manganese-enhanced MRI. Neuroimage (2011) 0.94
Axonal degeneration as a therapeutic target in the CNS. Cell Tissue Res (2012) 0.91
Amyloid β1-42 oligomer inhibits myelin sheet formation in vitro. Neurobiol Aging (2010) 0.90
Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease. Acta Neuropathol (2014) 0.90
Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits. J Neuroimmunol (2009) 0.89
Neurologic and motor dysfunctions in APP transgenic mice. Rev Neurosci (2012) 0.85
Prediction of S-glutathionylated proteins progression in Alzheimer's transgenic mouse model using principle component analysis. J Alzheimers Dis (2012) 0.83
Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy. Curr Neuropharmacol (2013) 0.83
Axonal degeneration in an Alzheimer mouse model is PS1 gene dose dependent and linked to intraneuronal Aβ accumulation. Front Aging Neurosci (2014) 0.82
TECPR2 Associated Neuroaxonal Dystrophy in Spanish Water Dogs. PLoS One (2015) 0.80
Amyloid plaque pathogenesis in 5XFAD mouse spinal cord: retrograde transneuronal modulation after peripheral nerve injury. Neurotox Res (2012) 0.77
Neuroprotective Effects Against POCD by Photobiomodulation: Evidence from Assembly/Disassembly of the Cytoskeleton. J Exp Neurosci (2016) 0.76
Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy. Ann Clin Transl Neurol (2016) 0.75
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem (2004) 5.14
Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem (2005) 4.23
PML in a patient treated with fumaric acid. N Engl J Med (2013) 3.87
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem (2007) 3.42
Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem (2002) 3.37
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27
Nonmalignant late effects after allogeneic stem cell transplantation. Blood (2003) 2.95
MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain (2006) 2.77
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst (2011) 2.56
Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci (2005) 2.48
19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci (2005) 2.44
Mutations in SIL1 cause Marinesco-Sjögren syndrome, a cerebellar ataxia with cataract and myopathy. Nat Genet (2005) 2.38
Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia (2005) 2.37
Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A (2004) 2.32
Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology (2006) 2.27
Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci (2010) 2.25
Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol (2004) 2.15
Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol (2013) 1.87
Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci (2007) 1.85
Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79
Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep (2012) 1.77
Repairing injured peripheral nerves: Bridging the gap. Prog Neurobiol (2010) 1.77
Potent amyloidogenicity and pathogenicity of Aβ43. Nat Neurosci (2011) 1.76
IL-6 is required for glioma development in a mouse model. Oncogene (2004) 1.74
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 1.70
Xenon reduces neurohistopathological damage and improves the early neurological deficit after cardiac arrest in pigs. Crit Care Med (2008) 1.70
The small GTPase Rab7 controls the endosomal trafficking and neuritogenic signaling of the nerve growth factor receptor TrkA. J Neurosci (2005) 1.69
A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade. J Neurochem (2004) 1.68
Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer (2005) 1.67
Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener (2011) 1.67
Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci (2004) 1.65
Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol (2006) 1.64
Dual roles for autophagy: degradation and secretion of Alzheimer's disease Aβ peptide. Bioessays (2014) 1.61
A de novo gain-of-function mutation in SCN11A causes loss of pain perception. Nat Genet (2013) 1.61
Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol (2004) 1.56
The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest (2005) 1.56
Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol (2003) 1.55
Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol Ther (2005) 1.54
Preparation and characterization of neurotoxic tau oligomers. Biochemistry (2010) 1.53
Combining xenon and mild therapeutic hypothermia preserves neurological function after prolonged cardiac arrest in pigs. Crit Care Med (2012) 1.53
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51
Chronic augmentation of the parasympathetic tone to the atrioventricular node: a nonthoracotomy neurostimulation technique for ventricular rate control during atrial fibrillation. J Cardiovasc Electrophysiol (2009) 1.51
Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, frabin/FGD4. Am J Hum Genet (2007) 1.50
Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med (2005) 1.49
Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl Acad Sci U S A (2005) 1.49
beta-amyloid is different in normal aging and in Alzheimer disease. J Biol Chem (2005) 1.48
Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab (2006) 1.47
Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging (2010) 1.46
Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry (2007) 1.44
Reducing the duration of 100% oxygen ventilation in the early reperfusion period after cardiopulmonary resuscitation decreases striatal brain damage. Resuscitation (2010) 1.44
Genes for hereditary sensory and autonomic neuropathies: a genotype-phenotype correlation. Brain (2009) 1.44
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol (2009) 1.44
Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest (2006) 1.43
Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res (2002) 1.43
Targeted high-throughput sequencing identifies mutations in atlastin-1 as a cause of hereditary sensory neuropathy type I. Am J Hum Genet (2010) 1.42
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med (2010) 1.41
Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs. Biochemistry (2006) 1.41
Argon: neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care (2009) 1.40
Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. Exp Gerontol (2005) 1.39
SH3TC2/KIAA1985 protein is required for proper myelination and the integrity of the node of Ranvier in the peripheral nervous system. Proc Natl Acad Sci U S A (2009) 1.39
Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem (2006) 1.37
Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J Biol Chem (2005) 1.34
Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42. Biochemistry (2004) 1.32
Aβ secretion and plaque formation depend on autophagy. Cell Rep (2013) 1.32
SIL1 mutations and clinical spectrum in patients with Marinesco-Sjogren syndrome. Brain (2013) 1.29
Endosomal transport of neurotrophins: roles in signaling and neurodegenerative diseases. Dev Neurobiol (2007) 1.29
Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci (2014) 1.28
ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem (2006) 1.28
Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J Biol Chem (2005) 1.25
Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem (2011) 1.24
Sortilin-related receptor with A-type repeats (SORLA) affects the amyloid precursor protein-dependent stimulation of ERK signaling and adult neurogenesis. J Biol Chem (2008) 1.24
Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One (2011) 1.23
Loss of M5 muscarinic acetylcholine receptors leads to cerebrovascular and neuronal abnormalities and cognitive deficits in mice. Neurobiol Dis (2006) 1.23
Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease. J Biol Chem (2011) 1.23
Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem (2010) 1.22
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm (Vienna) (2009) 1.22
Implantation and explantation of a wireless epiretinal retina implant device: observations during the EPIRET3 prospective clinical trial. Invest Ophthalmol Vis Sci (2009) 1.21
Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem Biophys Res Commun (2003) 1.21
The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate Abeta fibril formation without increasing protofibril formation. J Biol Chem (2006) 1.21
Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol (2006) 1.20
Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta -secretase (BACE1). J Biol Chem (2002) 1.20
In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J Neurosci (2011) 1.19
Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb Cortex (2002) 1.18
Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci (2009) 1.18
Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J (2011) 1.18
Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry (2008) 1.18
Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord (2010) 1.17
Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. J Neurosci Res (2010) 1.17
Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem (2010) 1.16
Autosomal-dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. Am J Hum Genet (2009) 1.16
Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol (2008) 1.16
Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res (2005) 1.16
Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol (2006) 1.16
Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am J Pathol (2005) 1.15
Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell (2008) 1.15